Een klein plukje aandeeltjes enteromedics en afwachten kan weinig kwaad natuurlijk. Daar raken we niet van in de goot, maar een beweging van een paar cent omhoog is al snel leuk lijkt mij.
EnteroMedics Inc. (NASDAQ:ETRM) stock is presently standing at about $0.05 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 2 analysts covering the company is $1.10, which suggests the stock could still rise over 95 percent. The highest analyst price target is $2.00, which implies a rally of -3800 percent. And a quick view of analyst notes show that 1 are rating the stock a buy while 0 rate ETRM a strong buy. There are 1 equity research firms advocating a Hold and 0 consider it Sell.
ROTH Capital analysts provided their view on EnteroMedics Inc. (NASDAQ:ETRM) recently. The rating firm issued a Neutral rating to this company in a research note released on Jun 09, 2016. Northland Securities analysts disclosed their opinion on EnteroMedics Inc. (NASDAQ:ETRM) recently. The rating firm gave a Outperform rating to this stock in a research note published on Jun 29, 2012. According to a research note disclosed on Jan 09, 2009, analysts at Argus have lowered their rating on these shares from Hold to Sell.
EnteroMedics Inc. (NASDAQ:ETRM) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its SVP, Ops & Bus Dev DeLange Peter M. Purchased 20,000 company shares for $11000, in a transaction on 2016-06-03. Following the transaction, the SVP, Ops & Bus Dev is left with a stake of 11 shares, currently valued at $1. Meanwhile, CEO GLADNEY DAN W purchased 50,000 shares worth $135000, through a transaction dated 2015-11-12. Following the completion of the transaction, the insider is left with a stake of 50,000 shares, amounting $2500. ETRM Chrmn, Pres & CEO KNUDSON MARK B also purchased 20,667 shares, at a stock price of $2.4. This transaction occurred on 2015-11-12 totals $49000.6. After this transaction, the insider’s stake stands at 45,011 shares, with a market value of $2251.
Executives hold 0.99 percent of the stock. Kevin G. Douglas is one of the biggest insider owners in EnteroMedics Inc. (NASDAQ:ETRM), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 3,010,852 shares which have current market value of around $150542.6.Mr. Dan W. Gladney is another major inside shareholder in the company. The insider owns 134,745 shares as of 0.12%, currently worth $6737.25. Dr. Mark B. Knudson, PhD is ranked as third insider holder of the stock. This insider holds 40,867 shares with a market value around $2043.35 as of recent close.
EnteroMedics Inc. (NASDAQ:ETRM) Earnings Outlook
In EnteroMedics Inc. (NASDAQ:ETRM)’s latest quarter, EPS moved to $-0.17 from $-0.49 in preceding quarter and revenues reached at $0.30M compared to $0.28M. Analysts had expected EnteroMedics Inc. (NASDAQ:ETRM) to post net income of about $-0.50 per share on $0.34M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.50 to $-0.38. That is compared with the $-0.95 in EPS it reported during the same period a year ago.
FacebookTwitterGoogle+PinterestLinke